A rare and serious drug reaction recently drew urgent attention after a 55-year-old woman developed sudden, painful skin symptoms following a change in her respiratory medication. What initially seemed like a routine adjustment quickly became a significant dermatological emergency, highlighting the need for caution whenever new medications are introduced—even those commonly prescribed.
The patient had a history of hypertension and chronic obstructive pulmonary disease (COPD), both well-controlled with enalapril and formoterol for several years. Her health had been stable, with no recent hospitalizations, infections, or major lifestyle changes.
Problems began shortly after her inhaler regimen was switched. Her formoterol-based treatment was replaced with a combination inhaler containing indacaterol and glycopyrronium, long-acting bronchodilators commonly used in COPD. Soon after, she developed alarming symptoms that could not be ignored.
She sought medical attention for intensely painful, red lesions on her face and neck, accompanied by a low-grade fever and general discomfort. The lesions were sharply defined, inflamed, and tender. She reported no recent exposure to new skincare products, cosmetics, household chemicals, diet changes, travel, insect bites, or infection symptoms. Her personal and family history was negative for autoimmune or dermatological conditions.
Due to the rapid onset and severity, she was referred urgently to dermatology. Clinicians suspected a drug-related reaction linked to her recent inhaler change. The indacaterol/glycopyrronium was immediately stopped, and she was started on oral corticosteroids to reduce inflammation and prevent progression.
Laboratory tests showed leukocytosis with neutrophilia, consistent with acute inflammation. Extensive serological testing ruled out infection, autoimmune disease, or systemic illness. Despite the dramatic skin findings, her vital signs were stable, and no organ involvement was detected.
Within 48 hours of stopping the medication and beginning corticosteroids, her symptoms improved significantly. Fever resolved, pain lessened, and the red plaques began to fade—strongly suggesting a drug-induced inflammatory reaction.
A skin biopsy confirmed the diagnosis: dense neutrophilic infiltration in the dermis without vasculitis, consistent with Sweet syndrome (acute febrile neutrophilic dermatosis).
Sweet syndrome is a rare inflammatory condition characterized by sudden, painful red or purple plaques, often with fever and elevated white blood cells. Its exact mechanism is unclear but likely involves immune dysregulation and abnormal neutrophil activation. Known triggers include infections, malignancies (especially hematologic cancers), autoimmune disorders, pregnancy, and certain medications.
What made this case unusual was that inhaled bronchodilators like indacaterol or glycopyrronium had not previously been associated with Sweet syndrome. Although drug-induced cases are more commonly reported in women, this medication class was a novel trigger, making the case clinically important.
The diagnosis required careful exclusion of similar conditions, such as urticaria, allergic contact dermatitis, toxic drug eruptions, lupus, and other inflammatory or autoimmune skin disorders. Each was ruled out based on clinical presentation, lab results, histology, and rapid improvement after stopping the suspected drug.
This case underscores a key lesson for clinicians, especially in primary care and pulmonology: even medications with established safety profiles can rarely cause severe reactions. When new symptoms appear soon after starting a medication—particularly with systemic signs like fever and inflammation—a drug reaction should be strongly considered.
Prompt recognition of Sweet syndrome is critical. Beyond treating the skin, patients often undergo broader evaluation for malignancies or autoimmune disease. In this case, no such associations were found, supporting the conclusion that the reaction was medication-induced.
Rapid discontinuation of the offending drug and initiation of corticosteroids led to swift improvement, preventing complications and prolonged suffering. Delayed recognition could have led to worsening symptoms, unnecessary treatments, or extensive investigations before identifying the true cause.
As the patient recovered, her COPD management was reassessed, with alternative therapies considered carefully. She was closely monitored, and no further dermatological issues occurred.
This case serves as a reminder that rare adverse drug reactions, though uncommon, are a real and important part of clinical practice. Thorough history-taking, attention to timing, and maintaining a broad differential are essential for patient safety and trust.
Post navigation
